Reviva Pharmaceuticals (RVPH) Competitors

Reviva Pharmaceuticals (NASDAQ:RVPH) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Is RVPH or CCCC more profitable?

Reviva Pharmaceuticals has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. Reviva Pharmaceuticals' return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	N/A	-252.53%
C4 Therapeutics	-313.35%	-42.45%	-27.55%

Which has more volatility & risk, RVPH or CCCC?

Reviva Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500.

Do analysts rate RVPH or CCCC?

Reviva Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 535.59%. C4 Therapeutics has a consensus target price of $10.67, suggesting a potential upside of 170.73%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33
C4 Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has higher valuation and earnings, RVPH or CCCC?

Reviva Pharmaceuticals has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$39.26M	-$1.11	-1.59
C4 Therapeutics	$20.76M	13.40	-$132.49M	-$1.70	-2.32

Does the media prefer RVPH or CCCC?

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Reviva Pharmaceuticals and 4 mentions for C4 Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.84 beat C4 Therapeutics' score of 0.48 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of RVPH or CCCC?

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer RVPH or CCCC?

C4 Therapeutics received 2 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 89.29% of users gave Reviva Pharmaceuticals an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote.

Company	Underperform	Outperform
Reviva Pharmaceuticals	Outperform Votes 25 89.29%	Underperform Votes 3 10.71%
C4 Therapeutics	Outperform Votes 27 39.13%	Underperform Votes 42 60.87%

Summary

Reviva Pharmaceuticals beats C4 Therapeutics on 13 of the 18 factors compared between the two stocks.